Quote | CureVac N.V. (NASDAQ:CVAC)
Last: | $2.77 |
---|---|
Change Percent: | -1.51% |
Open: | $2.69 |
Close: | $2.77 |
High: | $2.775 |
Low: | $2.61 |
Volume: | 406,948 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | CureVac N.V. (NASDAQ:CVAC)
2024-04-24 15:12:02 ET CureVac N.V. (CVAC) Q4 2023 Earnings Conference Call April 24, 2024 09:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications & Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendil...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Message Board Posts | CureVac N.V. (NASDAQ:CVAC)
Subject | By | Source | When |
---|---|---|---|
$CVAC CureVac NV | mick | investorshub | 04/30/2023 10:27:40 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 7:10:09 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:33 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:32 PM |
$CVAC CureVac NV | mick | investorshub | 02/26/2023 11:52:14 PM |
News, Short Squeeze, Breakout and More Instantly...
CureVac N.V. Company Name:
CVAC Stock Symbol:
NASDAQ Market:
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...